1. Home
  2. HON vs ARGX Comparison

HON vs ARGX Comparison

Compare HON & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Honeywell International Inc.

HON

Honeywell International Inc.

HOLD

Current Price

$245.60

Market Cap

76.4B

Sector

Industrials

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$865.67

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HON
ARGX
Founded
1885
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4B
58.4B
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
HON
ARGX
Price
$245.60
$865.67
Analyst Decision
Buy
Strong Buy
Analyst Count
13
19
Target Price
$249.92
$1,008.56
AVG Volume (30 Days)
3.0M
272.8K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.26%
N/A
EPS Growth
N/A
N/A
EPS
20.39
N/A
Revenue
$36,529,000,000.00
N/A
Revenue This Year
$6.74
$44.39
Revenue Next Year
$5.91
$20.84
P/E Ratio
$11.81
$33.69
Revenue Growth
12.92
N/A
52 Week Low
$186.76
$631.74
52 Week High
$252.00
$953.58

Technical Indicators

Market Signals
Indicator
HON
ARGX
Relative Strength Index (RSI) 55.00 50.64
Support Level $234.42 $822.56
Resistance Level $242.65 $881.89
Average True Range (ATR) 6.93 26.32
MACD 0.47 -2.43
Stochastic Oscillator 60.37 44.64

Price Performance

Historical Comparison
HON
ARGX

About HON Honeywell International Inc.

Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: